Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1568039

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1568039

Hydroxychloroquine

PUBLISHED:
PAGES: 293 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Hydroxychloroquine Market to Reach US$1.3 Billion by 2030

The global market for Hydroxychloroquine estimated at US$1.0 Billion in the year 2023, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2023-2030. Malaria Disease, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$644.0 Million by the end of the analysis period. Growth in the Rheumatoid Arthritis Disease segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$284.2 Million While China is Forecast to Grow at 6.3% CAGR

The Hydroxychloroquine market in the U.S. is estimated at US$284.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$268.3 Million by the year 2030 trailing a CAGR of 6.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Hydroxychloroquine Market - Key Trends and Drivers Summarized

What is Hydroxychloroquine, and Why Has It Garnered Global Attention?

Hydroxychloroquine is a medication that was originally developed to treat malaria but has since become widely used in the management of autoimmune disorders such as lupus and rheumatoid arthritis. It works by modulating the immune system and reducing inflammation, making it an effective therapeutic option for these chronic conditions. Chemically, hydroxychloroquine is a derivative of chloroquine, another antimalarial drug, but it is considered to have a better safety profile and fewer side effects. In recent years, hydroxychloroquine has gained unprecedented global attention due to its controversial and widely debated use as a potential treatment for COVID-19. Early in the pandemic, some preliminary studies and anecdotal evidence suggested that it might help in reducing the severity of the virus by inhibiting viral replication and modulating the immune response. This sparked a surge in demand and global interest in the drug, with some countries stockpiling it and doctors prescribing it off-label. However, subsequent large-scale clinical trials and scientific investigations yielded mixed results, leading to significant debate and confusion about its efficacy. Regulatory agencies like the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA) initially issued emergency use authorizations but later revoked them, citing a lack of conclusive evidence and potential safety concerns. This ongoing scrutiny has kept hydroxychloroquine in the spotlight, not just in the medical community but also in public discourse, making it one of the most talked-about drugs of recent times.

Who is Using Hydroxychloroquine, and What Are Its Main Medical Applications?

Hydroxychloroquine continues to be widely used in its approved indications, primarily as a disease-modifying antirheumatic drug (DMARD) for autoimmune conditions like lupus and rheumatoid arthritis. Patients suffering from these disorders often experience chronic inflammation and an overactive immune response, and hydroxychloroquine helps by modulating these processes to prevent flare-ups and manage symptoms. For lupus patients, in particular, the drug has proven to be invaluable, helping to control skin rashes, joint pain, and fatigue, and preventing organ damage associated with severe disease manifestations. Its use in rheumatoid arthritis is also well-documented, where it helps reduce joint swelling, pain, and the long-term damage caused by autoimmune activity. Beyond these established applications, hydroxychloroquine’s role as an antimalarial agent remains relevant in regions where malaria is endemic, although it is now largely used for prevention and in specific cases where resistance to newer antimalarials is not a concern. The COVID-19 pandemic brought a surge of off-label use among both healthcare professionals and the general public, fueled by early reports suggesting potential antiviral properties. This off-label usage led to shortages and raised concerns about access for patients who depend on the drug for chronic conditions. Despite the controversies, hydroxychloroquine’s immunomodulatory and anti-inflammatory properties have kept it under consideration for research in various other diseases, including Sjögren's syndrome and sarcoidosis. Thus, while its place in COVID-19 treatment has been largely debunked, hydroxychloroquine remains a critical medication for millions suffering from autoimmune diseases worldwide.

What Challenges and Controversies Surround Hydroxychloroquine?

Hydroxychloroquine has been at the center of a highly charged and complex controversy, driven by a combination of scientific uncertainty, political dynamics, and public misinformation. One of the biggest challenges is the conflicting data surrounding its safety and efficacy for uses beyond its approved indications. Early in the COVID-19 pandemic, small observational studies and in vitro experiments suggested potential benefits, leading to a wave of off-label use. However, as larger randomized controlled trials were conducted, many failed to show any significant clinical benefits, and some even reported adverse effects, particularly cardiovascular complications like arrhythmias and QT prolongation. This inconsistency in results led to confusion among both healthcare providers and the public, eroding trust in scientific research and regulatory bodies. Adding to the confusion was the politicization of the drug, with high-profile endorsements and misinformation campaigns creating a polarized debate that further muddied public perception. The initial hype led to widespread hoarding, stockpiling, and in some cases, self-medication, which resulted in toxicity and hospitalizations. This situation posed significant challenges for patients who rely on hydroxychloroquine for chronic conditions like lupus and rheumatoid arthritis, as shortages disrupted their treatment regimens. Additionally, regulatory decisions regarding hydroxychloroquine have been inconsistent, with agencies such as the FDA and the European Medicines Agency (EMA) issuing and then retracting emergency use authorizations. This regulatory back-and-forth has raised broader questions about the process of scientific validation and the role of politics in public health decision-making. Despite these controversies, hydroxychloroquine’s safety profile for its approved uses remains well-established, though its reputation has been undeniably affected by the turbulence of the past few years.

What Factors Are Driving the Continued Interest in Hydroxychloroquine?

The growth in interest and research into hydroxychloroquine is driven by several factors related to its established therapeutic benefits, ongoing scientific inquiries, and the quest for cost-effective treatment options. One of the main drivers is its long-standing use as a safe and effective treatment for autoimmune disorders, making it a mainstay in the management of diseases like lupus and rheumatoid arthritis. For patients with these chronic conditions, hydroxychloroquine has proven to be a reliable medication that reduces disease activity and prevents complications, with a relatively favorable side effect profile compared to other immunosuppressive drugs. This established efficacy has sustained interest in exploring its potential applications in other immune-mediated diseases, such as Sjögren’s syndrome and sarcoidosis, where inflammation and immune dysregulation play a key role. Another key factor driving interest is its affordability and widespread availability. As a generic drug, hydroxychloroquine is inexpensive compared to newer immunomodulatory or biologic therapies, making it an attractive option, particularly in low- and middle-income countries where healthcare resources are limited. Moreover, the controversies surrounding its use in COVID-19 have paradoxically fueled more research into its pharmacological properties, with some studies now focusing on understanding the exact mechanisms of action that contribute to its immunomodulatory effects. Researchers are looking into its impact on cytokine levels, potential benefits in preventing thrombotic complications, and its influence on various signaling pathways involved in immune response. As a result, hydroxychloroquine remains a subject of scientific inquiry, not just for its known applications, but also for its broader role in the pharmacological landscape of immunomodulatory treatments.

Select Competitors (Total 56 Featured) -

  • Abcam PLC
  • Amneal Pharmaceuticals, Inc.
  • Apotex, Inc.
  • Daicel Chiral Technologies (India) Pvt. Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Hetero Healthcare Ltd.
  • Ipca Laboratories Ltd.
  • Lifevision Healthcare
  • Lupin Ltd.
  • MilliporeSigma
Show more
Product Code: MCP24095

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Hydroxychloroquine - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Malaria in Endemic Regions Drives Growth in the Hydroxychloroquine Market
    • Increased Use of Hydroxychloroquine in the Treatment of Autoimmune Disorders Expands Market Potential
    • Growing Adoption for Rheumatoid Arthritis and Lupus Erythematosus Fuels Demand
    • Emerging Research on Hydroxychloroquine's Role in Managing Inflammatory Conditions Strengthens Market Scope
    • Rising Demand for Hydroxychloroquine in Developing Countries for Malaria Control Sustains Market Growth
    • Growing Emphasis on Chronic Disease Management Drives Long-Term Use of Hydroxychloroquine
    • Shifting Focus Towards Personalized Medicine in Autoimmune Disease Management Creates New Opportunities
    • Growing Use of Hydroxychloroquine in Combination Therapies Fuels Research and Development Initiatives
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hydroxychloroquine Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hydroxychloroquine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Malaria Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Malaria Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Malaria Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Rheumatoid Arthritis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Rheumatoid Arthritis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Homecare End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Hydroxychloroquine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Hydroxychloroquine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • INDIA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Hydroxychloroquine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Hydroxychloroquine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Hydroxychloroquine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AFRICA
    • Hydroxychloroquine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Hydroxychloroquine by Disease Type - Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Hydroxychloroquine by Disease Type - Percentage Breakdown of Value Sales for Malaria Disease, Rheumatoid Arthritis Disease and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Hydroxychloroquine by End-Use - Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Hydroxychloroquine by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Homecare End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!